Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch biotechnology company Crucell and technology partner DSM Biologics have signed a PER.C6 research license agreement with the Taiwan-based AbGenomics Corporation.
Subscribe to our email newsletter
AbGenomics Corporation intends to use the PER.C6 cell line for its research, development and early clinical studies of monoclonal antibodies.
“The unique characteristics of the PER.C6 technology as a human cell line combined with the short timeline involved in producing clinical material along with the technology’s robustness undoubtedly makes our choice for PER.C6 highly imperative,” said Shih-Yao Lin, AbGenomics Corporation’s president.
Under the terms of this agreement, AbGenomics Corporation will make license payments and annual maintenance fees in exchange for certain rights. Further financial details were not disclosed.